We recently published 12 Best Healthcare Stocks to Buy Under $30. MannKind Corporation (NASDAQ:MNKD) is one of the best ...

MannKind Corporation (NASDAQ:MNKD) presented inhaled insulin therapy at the American Diabetes Association’s 85th Scientific Sessions in Chicago, which was held from June 20 to June 23, 2025.

MannKind Corporation (NASDAQ:MNKD) presented inhaled insulin therapy at the American Diabetes Association’s 85th Scientific Sessions in Chicago, which was held from June 20 to June 23, 2025. Dr.

MannKind saw decent growth from its two core products in Q2 and just signed a new non-dilutive financing agreement with ...

MannKind (NASDAQ:MNKD), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most si ...

MannKind Corporation (NASDAQ:MNKD) presented inhaled insulin therapy at the American Diabetes Association’s 85th Scientific Sessions in Chicago, which was held from June 20 to June 23, 2025.

Ultra-rapid insulins are used to manage type 1 and type 2 diabetes. Learn about the different types, their effectiveness, and how they can provide mealtime flexibility.

Conference call today at 9:00 am ET2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD ...

As San Diego County braces for triple-digit temperatures, pharmacists urge residents to protect heat-sensitive medications ...

The company submitted its lead inhaled insulin product for expanded FDA approval and secured $500 million in funding, it said ...